Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the appointment of Aaron ...

Researchers from Mass General Brigham , Harvard Medical School and Duke University School of Medicine have identified nearly ...

Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms ...

Aaron joins Freenome most recently from REALM IDx, Inc., where he served as CEO and president for nearly four years, overseeing its subsidiaries Ambry Genetics, Invicro and Konica Minolta REALM-Japan.

Researchers from Mass General Brigham, Harvard Medical School and Duke University School of Medicine have identified nearly 300 genetic disorders that can be treated before or immediately after a baby ...

In February 2025, Tempus AI, Inc. (NASDAQ:TEM) completed the acquisition of Ambry Genetics, enhancing its capabilities in genetic testing and data services. Tempus’s stock has experienced ...

Tempus "increased" its 2025 revenue guidance from $1.23 billion to $1.24 billion (for the consolidated Tempus and Ambry Genetics business), with adjusted EBITDA of “approximately $5 million.” ...

Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark broader industry growth?

We recently published a list of 10 Stocks That Will Profit From AI. In this article, we are going to take a look at where ...

including our ability to realize the expected benefits of the acquisition of Ambry Genetics; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic ...